Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002–2006. A nationwide study including correlation between HER-2 status and other prognostic variables
暂无分享,去创建一个
[1] K. Kwok,et al. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm , 2006, Modern Pathology.
[2] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[3] R. Gelber,et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] M. Press,et al. Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab , 2005, Breast Cancer Research and Treatment.
[5] A. Hanby,et al. Testing for HER2 in breast cancer , 2004, Histopathology.
[6] M. Ladanyi,et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. , 2004, American journal of clinical pathology.
[7] I. Ellis,et al. Best Practice No 176 , 2004, Journal of Clinical Pathology.
[8] E D Hsi,et al. Guidelines for HER2 testing in the UK , 2004, Journal of Clinical Pathology.
[9] C. Cohen,et al. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. , 2003, Human pathology.
[10] M. Dowsett,et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres , 2003, The Journal of pathology.
[11] J. Bartlett,et al. The clinical evaluation of HER‐2 status: which test to use? , 2003, The Journal of pathology.
[12] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.